英夫利昔单抗治疗炎症性肠病后诱发银屑病的研究进展

Abstract
Figure/Table
References (51)
Related Citation (15)

Download: PDF (0 KB) HTML (52 KB)
Export: BibTeX | EndNote (RIS)

Abstract Infliximab(IFX)is a monoclonal immunoglobulin G1 antibody against tumor necrosis factor-α which has been widely used in the treatment of inflammatory bowel disease(IBD)and psoriasis in China,and the effect is remarkable.It is interesting to note that in recent years,the reports of psoriasis induced by IFX in IBD have gradually increased.Psoriasis,as the complication of IBD,aggravates the patients′suffering,and its characteristics,pathogenesis,prevention,diagnosis,treatment are urgently needed to be solved.In the treatment of IBD,the pathogenesis of psoriasis may be related to immune,genetic,IFX concentration and other factors.A review was performed to provide information about the research progress of psoriasis induced by IFX in IBD.

Key words： Inflammatory bowel disease Psoriasis Infliximab Pathogenesis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Lian-yu
	WU Jing
	ZHANG Feng-rui
	MIAO Ying-lei

Cite this article:

ZHOU Lian-yu,WU Jing,ZHANG Feng-rui, et al. Research progress of psoriasis induced by Infliximab in the treatment of inflammatory bowel disease[J]. 中国当代医药, 2021, 28(15): 43-47转51.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I15/43

[1]	Rutgeerts P，Sandborn WJ，Feagan BG，et al.Infliximab for induction and maintenance therapy for ulcerative colitis[J].N Engl J Med，2005，353（23）：2462-2467.
[2]	Ng SC.Emerging Trends of Inflammatory Bowel Disease in Asia[J].Gastroenterol Hepatol（N Y），2016，12（3）：193-196.
[3]	Kaplan GG.The global burden of IBD：from 2015 to 2025[J].Nat Rev Gastroenterol Hepatol，2015，12（12）：720-727.
[4]	Ding X，Wang T，Shen Y，et al.Prevalence of psoriasis in China：a population.based study，in six cities[J].Eur J Dermatol，2012，22（5）：663-667.
[5]	Michalek IM，Loring B，John SM，et al.A systematic review of worldwide epidemiology of psoriasis[J].Eur Acad Dermatol Venereol，2017，31（2）：205-212.
[6]	Nestle FO，Kaplan DH，Barker J.Psoriasis[J].N Engl J Med，2009，361（5）：496-509.
[8]	De Lange KM，Barrett JC.Understanding inflammatory bowel disease via immunogenetics[J].Autoimmun，2015，64：91-100.
[12]	刘爱玲，吕红，李玥，等.英夫利昔单抗治疗炎症性肠病95例不良反应及其危险因素分析[J].中国实用内科杂志，2018，38（3）：217-222.
[13]	Najarian DJ，Gottlieb AB.Connections between psoriasis and Crohn′s disease[J].Am Acad Dermatol，2003，48（6）：805-821.
[7]	Binus AM，Han J，Oamar AA，et al.Associated comorbidities in psoriasis And inflammatory bowel disease[J].Eur Acad Dermatol Venereol，2012，26（5）：644-650.
[9]	Langley RGB，Kreuger GG，Griffiths CEM.Psoriasis：epidemiology，clinical features，and quality of life[J].Ann Rheum Dis，2005，64（2）：18-23.
[10]	Hanauer SB，Feagan BG，Lichtenstein GR，et al.Maintenance infliximab for Crohn′s disease：the ACCENT I randomised trial[J].Lancet，2002，359（9317）：1541-1549.
[11]	Fu Y，Lee CH，Chi CC.Association of Psoriasis With Inflammatory Bowel Disease：A Systematic Review and Metaanalysis[J].JAMA Dermatol，2018，154（12）：1417-1424.
[14]	Bar YS，Axlerod R，Toker O，et al.The association of Inflammatory Bowel diseases with autoimmune disorders：a population-based report from the epi-ⅡRN[J].J Crohns Colitis，2019.13（3）：324-329.
[15]	Eickstaedt JB，Killpack L，Tung J，et al.Tollefson MM.Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treatedwith Anti-Tumor Necrosis Factor α Agents[J].Pediatr Dermatol，2017，34（3）：253-260.
[16]	Sridhar S，Maltz RM，Boyle B，et al.Dermatological Manifestations in Pediatric Patients with Inflammatory Bowel Diseases on Anti-TNF Therapy[J].Inflamm Bowel Dis，2018，24（9）：2086-2092.
[17]	Guerra I，Algaba A，Pérez-Calle JL，et al.Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease：A report of 21 cases[J].J Crohns Colitis，2012，6（5）：518-523.
[18]	Peer FC，Miller A，Pavli P，et al.Paradoxical Psoriasiform Reactions of Anti-Tumour Necrosis Factor Therapy in Inflammatory Bowel Disease Patients[J].Intern Med J，2017，47（12）：1445-1448.
[19]	Udkoff J，Cohen PR.Severe Infliximab-Induced Alopecia and Scalp Psoriasis in a Woman with Crohn′s Disease：Dramatic Improvement after Drug Discontinuation and Treatment with Adjuvant Systemic and Topical Therapies[J].Dermatol Ther（Heidelb），2016，6（4）：689-695.
[20]	Steinwurz F，Denadai R，Saad-Hossne R，et al.Infliximabinduced psoriasis during therapy for Crohn′s disease[J].J Crohns Colitis，2012，6（5）：610-616.
[21]	Passarini B，Infusino SD，Barbieri E，et al.Cutaneous manifestations in inflammatory bowel diseases：eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy[J].Dermatology，2007，215（4）：295-300.
[42]	Lees CW，Barrett JC，Parkes M，et al.New IBD genetics：common pathways with other diseases[J].Gut，2011，60（12）：1739-1753.
[43]	Boehncke WH.Psoriasis and psoriatic arthritis：flip sides of the coin?[J].Acta Derm Venereol，2016，96（4）：436-441.
[22]	Loh TY，Cohen PR.Infliximab-associated psoriasiform dermatitis：case report and review of a seemingly paradoxical inflammatory response[J].Cureus，2016，8（9）：773.
[23]	Medkour F，Babai S，Chanteloup E，et al.Development of diffuse psoriasis with alopecia during treatment of Crohn′s disease with infliximab[J].Gastroenterol Clin Biol，2010，34（2）：140-141.
[24]	Oppmann B，Lesley R，Blom B，et al.Novel p19 protein engages IL-12 p40 to form a cytokine，IL-23，with biological activities similar as well as distinct from IL-12[J].Immunity，2000，13（5）：715-725.
[25]	Aggarwal S，Ghilardi N，Xie MH，et al.Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17[J].Biol Chem，2003，278（3）：1910-1914.
[26]	de Gannes GC，Ghoreishi M，Pope J，et al.Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions[J].Arch Dermatol，2007，143（2）：223-231.
[27]	Patel U，Mark NM，Machler BC，et al.Imiquimod 5% cream induced psoriasis：a case report，summary of the literature and mechanism[J].Br J Dermatol，2011，164（3）：670-672.
[28]	Collamer AN，Battafarano DF.Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy：clinical features and possible immunopathogenesis[J].Semin Arthritis Rheum，2010，40（3）：233-240.
[29]	Seneschal J，Milpied B，Vergier B，et al.Cytokine imbalance with increased production of interferon-α in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments[J].Br J Dermatol，2009，161（5）：1081-1088.
[30]	Chan JR，Blumenschein W，Murphy E，et al.IL-23 stimulates epidermal hyperplasia via TNF and IL-20 R2-dependent mechanisms with implications for psoriasis pathogenesis[J].Exp Med，2006，203（12）：2577-2587.
[31]	Di Cesare A，Di Meglio P，Nestle FO.The IL-23/Th17 axis in the immunopathogenesis of psoriasis[J].Invest Dermatol，2009，129（6）：1339-1350.
[32]	Stritesky GL，Yeh N，Kaplan MH.IL-23 promotes maintenance but not commitment to the Th17 lineage[J].J Immunol，2008，181（9）：5948-5955.
[33]	Volpe E，Servant N，Zollinger R，et al.A critical function for transforming growth factor-beta，interleukin 23 and proinflammatory cytokines indriving and modulating human T（H）-17 responses[J].Nat Immunol，2008，9（6）：650-657.
[37]	Skroza N，Proietti I，Pampena R，et al.Correlations between psoriasis and inflammatory bowel diseases[J].Biomed Res Int，2013，201：983-902.
[38]	陈白莉，钱家鸣，吴开春，等.英夫利昔单抗治疗活动性溃疡性结肠炎疗效与安全性的临床研究[J].中华炎症性肠病杂志（中英文），2017，（1）：20-23.
[34]	Sakkas LI，Bogdanos DP.Are psoriasis and psoriatic arthritis the same disease？The IL-23/IL-17 axis data[J].Autoimmun Rev，2017，16（1）：10-15.
[35]	Wang Y，Mao Y，Zhang JF，et al.IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells[J].J Cell Mol Med，2017，22（2）：1014-1025.
[36]	Hawkes JE，Chan TC，Krueger JG，et al.Psoriasis pathogenesis and the development of novel targeted immune therapies[J].Allergy Clin Immunol，2017，140（3）：645-653.
[39]	Elder JT，Nair RP，Henseler T，et al.The Genetics of Psoriasis 2001：The odyssey continues[J].Arch Dermatol，2001，137（11）：1447-1454.
[40]	Capon F，Burden AD，Trembath RC，et al.Psoriasis and other complex trait dermatoses：from Loci to functional pathways[J].Invest Dermatol，2012，132（3 Pt 2）：915-922.
[41]	Stuart PE，Nair RP，Tsoi LC，et al.Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture[J].Am J Hum Genet，2015，97（6）：816-836.
[44]	Protic M，Schoepfer A，Yawalkar N，et al.Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough level[J].Scand J Gastroenterol，2016，51（12）：1482-1488.
[45]	Huang V，Dhami N，Fedorak D，et al.A study investigating the association of dermatological and infusion reactions to infliximab and Infliximab trough levels[J].Can J Gastroenterol Hepatol，2015，29（1）：35-40.
[46]	Lee D，Albenberg L，Compher C，et al.Diet in the pathogenesis and treatment of inflammatory bowel diseases[J].Gastroenterology，2015，148（6）：1087-1106.
[47]	Walker AW，Sanderson JD，Churcher C，et al.High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease[J].BMC Microbiol，2012，11（1）：7.
[48]	Kiyohara H，Sujino T，Teratani T，et al.Toll-Like Receptor 7 Agonist-Induced Dermatitis Causes Severe Dextran Sulfate Sodium Colitis by Altering the Gut Microbiome and Immune Cells[J].Cell Mol Gastroenterol Hepatol，2019，7（1）：135-156.
[49]	Ribeiro LBP，Rego JCG，Estrada BD，et al.Alopecia secondary to anti-tumor necrosis factor-α therapy[J].An Bras Dermatol，2015，90（2）：232-235.
[50]	Bae JM，Lee HH，Lee BI，et al.Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease：a nationwide population-based cohort study[J].Aliment Pharmacol Ther，2018，48（2）：196-205.
[51]	Courbette O，Aupiais C，Viala J，et al.Infliximab Paradoxical Psoriasis in a Cohort of Children With Inflammatory Bowel Disease[J].Pediatr Gastroenterol Nutr，2019，69（2）：189-193.

[1]	DONG Yu-xin;NA Ren-gao-wa▲;LIU Yuan-fan;QI Xiao-xuan;HOU Yuan;WANG Tian-ci;GAO Rui-rong;WANG Yan-shu. Research progress of diabetic nephropathy[J]. 中国当代医药, 2021, 28(9): 35-38.